Lilly Eli & Co (NYSE:LLY) Big Money Sentiment Up in Q4 2017 to 1.1

May 17, 2018 - By Julia Grubbs

Eli Lilly and Company (NYSE:LLY) Corporate Logo

“Big money” Positions

In 2017 Q4 Lilly Eli & Co (NYSE:LLY) big money sentiment increased to 1.1, according to SEC filings. So its up 0.21, from 2017Q3’s 0.89. 463 funds started new or increased stock positions, while 422 reduced and sold holdings in Lilly Eli & Co so the sentiment has increased. Funds own 827.08 million shares, down from 827.83 million shares in 2017Q3. Funds holding Lilly Eli & Co in top 10 changed to 15 from 19 for a decrease of 4. In total 42 funds closed positions, 380 reduced and 346 increased. Also 117 funds bought new Lilly Eli & Co stakes.

Largest Lilly Eli & Co Investors

Lilly Endowment Inc owns 123.08 million shares in Lilly Eli & Co as of 2017 Q4. As of 2017 Q4, 385,549 shares of Lilly Eli & Co are owned by Private Capital Advisors Inc.. Weatherly Asset Management L. P. reported 327,825 shares. Healthinvest Partners Ab revealed 32,000 shares position in Lilly Eli & Co. The New York-based fund Valueworks Llc holds 69,752 shares or 4.38% of their US long stock exposure.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide.The firm is valued at $82.86 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products.Currently it has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

LLY is touching $81.18 during the last trading session, after decreased 0.57%.Currently Eli Lilly and Company is downtrending after 10.19% change in last May 17, 2017. LLY has also 3.61M shares volume. The stock underperformed the S&P500 by 21.74%.

Investors wait Eli Lilly and Company (NYSE:LLY)’s quarterly earnings on July, 24., Faxor reports. Analysts have anticipation on stock’s earnings per share of $1.34. That’s up 20.72 % from last year’s $1.11 earnings per share. If the current earnings per share of $1.34 is accurate, LLY’s profit could hit $1.37B. 0.00 % EPS growth is what analysts predict. $1.34 earnings per share was announced for previous quarter.

Manchester Capital Mngmt Ltd invested in 0.03% or 2,210 shs. Ashfield Ptnrs reported 2,428 shs or 0.03% of all its holdings. Campbell Adviser Lc reported 10,087 shs stake. 12,076 were reported by Fiduciary Serv Of The Southwest Tx. Savant Limited Com holds 7,584 shs. Parametric Port Associate Lc accumulated 0.2% or 2.37 million shs. Cullen Frost Bankers invested in 0.08% or 30,467 shs. Wade G W holds 0.07% or 6,792 shs. Dearborn Partners Limited Liability Company invested in 0.02% or 3,270 shs. Mechanics National Bank & Trust Department has invested 0.1% in Eli Lilly and Company (NYSE:LLY). Klingenstein Fields And Llc has 316,990 shs for 0.99% of their capital. Peddock Advsr Ltd Liability Co stated it has 0.23% of its capital in Eli Lilly and Company (NYSE:LLY). Magnetar Financial Ltd Liability reported 24,684 shs. Ahl Prtn Llp stated it has 0.05% in Eli Lilly and Company (NYSE:LLY). Parkside Bankshares &, Missouri-based fund reported 3,841 shs.

Eli Lilly and Company registered $48.49 million net activity with 0 insider buys and 11 sales since December 11, 2017. On Wednesday, December 13 LILLY ENDOWMENT INC sold $17.64M worth of Eli Lilly and Company (NYSE:LLY) or 200,000 shs. On Monday, February 5 Zakrowski Donald A had sold 900 shs worth $72,981. On Thursday, February 1 9,625 shs were sold by Simmons Jeffrey N, worth $780,780. Smiley Joshua L sold 3,000 shs worth $237,600.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

In total 10 analysts cover Eli Lilly (NYSE:LLY). “Buy” rating has 4, “Sell” are 1, while 5 are “Hold”. (NYSE:LLY) has 40% bullish analysts. With $105.0 highest and $74 lowest target, Eli Lilly has $90.50 average target or 11.48% above the current ($81.18) price. 17 are the (NYSE:LLY)’s ratings reports on 17 May 2018 according to StockzIntelligence Inc. On Monday, January 22 the stock of Eli Lilly and Company (NYSE:LLY) has “Underperform” rating given by Credit Suisse. On Thursday, February 1 the rating was maintained by Leerink Swann with “Hold”. On Friday, April 13 the firm has “Buy” rating given by Jefferies. On Wednesday, December 13 the firm earned “Hold” rating by Leerink Swann. The company rating was maintained by BMO Capital Markets on Thursday, February 1. On Wednesday, April 25 BMO Capital Markets maintained the shares of LLY in report with “Market Perform” rating. On Tuesday, January 16 the rating was maintained by Jefferies with “Buy”. On Friday, January 5 the firm earned “Buy” rating by Argus Research. On Friday, April 13 BMO Capital Markets upgraded the shares of LLY in report to “Market Perform” rating. On Wednesday, December 13 the firm earned “Hold” rating by Credit Suisse.

For more Eli Lilly and Company (NYSE:LLY) news posted briefly go to: 247Wallst.com, Streetinsider.com, Bizjournals.com, Streetinsider.com or Benzinga.com. The titles are as follows: “Will the FDA Shoot Down Eli Lilly and Incyte Again?” posted on April 20, 2018, “Lilly (LLY) to Acquire ARMO BioSciences (ARMO) for $50/Share” on May 10, 2018, “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs” with a publish date: May 10, 2018, “Eli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer Care” and the last “Upcoming Earnings: CAT, LLY And BA Report This Week” with publication date: April 23, 2018.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: